{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:34:40Z","timestamp":1770143680838,"version":"3.49.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Patients with relapsed or refractory multiple myeloma (RRMM) are likely to be living with persistent symptoms, especially bone pain and fatigue, and experiencing restrictions in their physical and social functioning, which reduce health-related quality of life.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This qualitative interview study evaluated patients\u2019 perspectives about living with RRMM and their treatment with belantamab mafodotin, using interviews embedded in the Phase II DREAMM-2 trial (NCT03525678) with belantamab mafodotin. Patients consented to participate in up to 2 recorded telephone interviews (at treatment cycle 4 [C4] and at end of treatment [EOT]) comprising open-ended questions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 142 interviews were conducted with 111 unique patients. At C4, common symptoms included neuropathy, fatigue, and bone or joint pain. Improvements in symptom severity were reported by patients who responded to belantamab mafodotin. Symptoms associated with visual impairment, eye irritation, and eye pain reported during the trial were reported to be at- or near-resolution by the EOT interview. Regarding impacts of underlying MM, patients most commonly expressed concerns about changes in daily performance and lifestyle for both responders (67.5% of all impact expressions) and non-responders (63.2%). Overall, interview participants reported being satisfied with belantamab mafodotin treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This qualitative patient interview study provides valuable insight into patients\u2019 symptomatic experience with belantamab mafodotin for their RRMM treatment and may help healthcare providers better anticipate their patients\u2019 real-world experience and needs when prescribing this novel agent in the clinic.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1274659","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T11:20:51Z","timestamp":1701948051000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed\/refractory multiple myeloma in the DREAMM-2 study"],"prefix":"10.3389","volume":"13","author":[{"given":"Anna","family":"Cardellino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia R.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Gorsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandhya","family":"Sapra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: A systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s12885-021-08280-y","article-title":"Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-019-01465-3","article-title":"Patient-reported measures of well-being in older multiple myeloma patients: use of secondary data source","volume":"32","author":"Cenzer","year":"2020","journal-title":"Aging Clin Exp Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-019-02392-6","article-title":"How are patient-reported outcomes and symptoms being measured in adults with relapsed\/refractory multiple myeloma? A systematic review","volume":"29","author":"LeBlanc","year":"2020","journal-title":"Qual Life Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1097\/HS9.0000000000000045","article-title":"Long-term outcomes in patients with multiple myeloma: A retrospective analysis of the Dutch population-based haematological registry for observational studies (PHAROS)","volume":"2","author":"Verelst","year":"2018","journal-title":"Hemasphere"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to Cd38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e1603","DOI":"10.1002\/cnr2.1603","article-title":"The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies","volume":"5","author":"Crawford","year":"2022","journal-title":"Cancer Rep (Hoboken NJ)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7561","article-title":"Symptom burden, perceived control, and quality of life among patients living with multiple myeloma","volume":"18","author":"Zaleta","year":"2020","journal-title":"J Natl Compr Cancer Netw: JNCCN"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17887","article-title":"Patient-reported outcomes in relapsed\/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the phase Ii horizon study","volume":"196","author":"Larocca","year":"2022","journal-title":"Br J Haematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-021-00501-7","article-title":"Patient perceptions regarding multiple myeloma and its treatment: qualitative evidence from interviews with patients in the United Kingdom, France, and Germany","volume":"14","author":"He","year":"2021","journal-title":"Patient"},{"key":"B12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41408-021-00543-y","article-title":"Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement","volume":"11","author":"Fernandes","year":"2021","journal-title":"Blood Cancer J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05493-y","article-title":"Symptom burden and its functional impact in patients with \u201cSymptomatic\u201d Relapsed or refractory multiple myeloma","volume":"29","author":"Kamal","year":"2021","journal-title":"Support Care Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0724","article-title":"Patient-reported factors in treatment satisfaction in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"24","author":"Chari","year":"2019","journal-title":"Oncologist"},{"key":"B15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.leukres.2017.05.019","article-title":"Living with the burden of relapse in multiple myeloma from the patient and physician perspective","volume":"59","author":"Hulin","year":"2017","journal-title":"Leuk Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti\u2013B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33809","article-title":"Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study","volume":"127","author":"Lonial","year":"2021","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody-drug conjugates in human clinical trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody\u2013drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41408-020-00369-0","article-title":"Single-agent belantamab mafodotin for relapsed\/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study","volume":"10","author":"Richardson","year":"2020","journal-title":"Blood Cancer J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.06.014","article-title":"Content validity\u2013establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1\u2013eliciting concepts for a new PRO instrument","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e0232076","DOI":"10.1371\/journal.pone.0232076","article-title":"A simple method to assess and report thematic saturation in qualitative research","volume":"15","author":"Guest","year":"2020","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12885-019-5467-x","article-title":"Treatment preferences of patients with relapsed and refractory multiple myeloma: A qualitative study","volume":"19","author":"Parsons","year":"2019","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1274659\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T11:20:53Z","timestamp":1701948053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1274659\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":24,"alternative-id":["10.3389\/fonc.2023.1274659"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1274659","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,7]]},"article-number":"1274659"}}